Special Issue "Novel Therapies for the Treatment of Metastatic Prostate Cancer"
Deadline for manuscript submissions: 22 February 2024 | Viewed by 573
Prostate cancer remains one of the top cancers diagnosed in men worldwide. While initial treatments are effective, once metastasis develops, the disease is fatal, with a 5-year survival of 30%. The last decade has led to the development and introduction of several novel agents, as well as the repurposing of others. In 2018–2019, anti-androgens abiraterone, apalutamide, and enzalutamide all received Federal Drug Administration (FDA) approval for metastatic castrate-sensitive prostate cancer (mCSPC). In addition, Relugolix, a highly selective oral gonadotropin-releasing hormone receptor antagonist, was approved for mCSPC based on the HERO (NCT03085095) trial results. The metastatic castrate-resistant prostate cancer (mCRPC) armamentarium for treatment includes docetaxel and cabazitaxel, abiraterone, enzalutamide, Radium-223, and the immunotherapy options of sipuleucel-T or prembrolizumab. More recent approvals include Olaparib for patients who previously progressed on enzalutamide or abiraterone and who carry alterations (germline and/or somatic) selected DNA damage and repair genes, as demonstrated in the PROfound (NCT02987543) trial. Another PARP inhibitor, Rucaparib, was approved in patients harboring a deleterious BRCA mutation (germline and/or somatic) who have been treated with an androgen receptor-directed therapy and taxane-based chemotherapy, following the results from the TRITON2 (NCT02952534) trial. More recently, the radioligand0based therapy, 177Lu-PSMA-617, was granted priority review for patients in the post-androgen receptor pathway inhibition and post-taxane-based chemotherapy setting based on data from the VISION (NCT03511664) trial. Future research focuses on the interrogation and targeting of different molecular pathways, including PTEN-loss, DNA repair defects, autophagy, epigenetics, and inflammation, all with the potential for therapeutic intervention alone or in combination with approved agents to improve the duration of response and reduce the development of resistance. In addition, extensive research is underway to understand the immune context of prostate cancer and the identification of immune-based interventions that may benefit patients. With the increased interrogation of genomic and molecular data, the list of novel therapies being investigated for metastatic prostate cancer remains vast and ranges from early preclinical drug development through to phase III clinical trials with the goal of identification of treatments that change the paradigm for patient outcomes with metastatic disease.
In this Special Issue, we aim to highlight cutting-edge research on novel therapeutic agents and strategies for treating metastatic prostate cancer.
Dr. Melissa LaBonte LaBonte Wilson
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- prostate cancer
- drug resistance
- androgen receptor-signaling inhibitors
- bipolar androgen therapy
- EZH2 inhibition
- autophagy inhibition
- prostate-specific membrane antigen-targeted therapy
- DNA repair inhibition
- PI3K/AKT/mTOR inhibition
- metastasis- and prostate-directed radiotherapy
- tumor microenvironment